Review
Oncology
Peyman Tabnak, Aysa Hasanzade Bashkandi, Mohammad Ebrahimnezhad, Mahdieh Soleimani
Summary: This review discusses the roles of transcription factors FOXOs and FOXM1 in gliomas, including their interactions with other proteins and microRNAs in regulatory networks, as well as their significance in glioma progression.
CANCER CELL INTERNATIONAL
(2023)
Review
Oncology
Cassie Liu, Carter J. Barger, Adam R. Karpf
Summary: Ovarian cancer is a lethal disease with a low 10-year survival rate worldwide, and the aberrant expression and activation of FOXM1 is a key molecular alteration in this cancer. FOXM1 is a master transcriptional regulator that promotes critical oncogenic phenotypes in ovarian cancer, making it a potential target for cancer therapy.
Review
Rheumatology
Suravi Raychaudhuri, Karmtej Singh Cheema, Smriti K. Raychaudhuri, Siba P. Raychaudhuri
Summary: This review focuses on the significance of JAK-STAT signaling proteins in SpA and discusses the development of new-generation JAK-STAT inhibitors for the treatment of SpA.
CURRENT OPINION IN RHEUMATOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Haojie Cheng, Jie Yuan, Chaozhu Pei, Min Ouyang, Huitong Bu, Yan Chen, Xiaoqin Huang, Zhenwang Zhang, Li Yu, Yongjun Tan
Summary: This study developed an interfering peptide M1-21 targeting the transcription factor FOXM1 and evaluated its anti-cancer efficacy. M1-21 inhibits the interaction between FOXM1 and its partner proteins, leading to the inhibition of cancer cell proliferation and migration, and affecting its transcriptional activities.
CELL AND BIOSCIENCE
(2023)
Article
Cell Biology
Yuankun Chen, Yijun Yang, Nengyi Wang, Rui Liu, Qiuping Wu, Hua Pei, Wenting Li
Summary: This study demonstrates the inhibitory effects of beta-sitosterol on hepatocellular carcinoma (HCC) growth and metastasis. Beta-sitosterol downregulates the expression of forkhead box M1 (FOXM1) and inhibits Wnt/beta-catenin signaling, resulting in the suppression of HCC cell proliferation and metastasis. These findings highlight the potential of beta-sitosterol as a therapeutic candidate for HCC treatment.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2023)
Article
Oncology
Ai-Ni Tsao, Yu-Syuan Chuang, Yen-Chun Lin, Yeu Su, Ta-Chung Chao
Summary: CDK4/6 inhibitors combined with endocrine therapy are the standard treatment for breast cancer. However, CDKs have potential roles beyond cell cycle regulation. Dinaciclib, a CDK inhibitor, inhibits breast cancer stemness and shows potential for future cancer treatment.
Article
Immunology
Jing Chen, Pusheng Yang, Shaojing Li, Yichen Feng
Summary: This study found that FOXM1 is highly expressed in endometrial cancer (EC) and is closely correlated with patient prognosis. FOXM1 genetic alteration was confirmed in EC patients, and it plays a role in the cell cycle and immune cell infiltration in EC. Furthermore, FOXM1 induces increased expression of CD276 and enhances neutrophil recruitment in EC. FOXM1 could be considered as a potential prognostic biomarker and immunotherapeutic target in the diagnosis and treatment of EC.
JOURNAL OF IMMUNOLOGY RESEARCH
(2023)
Article
Cell Biology
Huitong Bu, Xianling Lan, Haojie Cheng, Chaozhu Pei, Min Ouyang, Yan Chen, Xiaoqin Huang, Li Yu, Yongjun Tan
Summary: Disrupting protein-protein interactions has emerged as a promising strategy for cancer drug development. Using a rational design approach, a peptide library was generated from the FOXM1 C-terminal sequence and a FOXM1-targeting interfering peptide M1-20 was obtained. M1-20 has the potential to be developed as an anti-cancer drug candidate targeting FOXM1.
CELL DEATH & DISEASE
(2023)
Article
Oncology
Deeptashree Nandi, Pradeep Singh Cheema, Aakriti Singal, Hina Bharti, Alo Nag
Summary: FoxM1 overexpression is associated with tumor aggressiveness, while Artemisinin has been identified to curb its activity and potentially improve therapeutic response, especially in resistant liver cancer cells. The combination of Artemisinin with Thiostrepton showed enhanced efficacy in reducing growth and inducing cell death in liver cancer cells, providing a novel therapeutic option for resistant cancer patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Hisashi Takeshita, Ryoji Yoshida, Junki Inoue, Kohei Ishikawa, Kosuke Shinohara, Mayumi Hirayama, Toru Oyama, Ryuta Kubo, Keisuke Yamana, Yuka Nagao, Shunsuke Gohara, Junki Sakata, Hikaru Nakashima, Yuichiro Matsuoka, Masafumi Nakamoto, Masatoshi Hirayama, Kenta Kawahara, Nozomu Takahashi, Akiyuki Hirosue, Yoshikazu Kuwahara, Manabu Fukumoto, Ryo Toya, Ryuji Murakami, Hideki Nakayama
Summary: Radioresistance is a major challenge in the treatment of oral squamous cell carcinoma (OSCC). In this study, we developed clinically relevant radioresistant (CRR) cell lines to investigate the regulation of radioresistance in OSCC cells. We found that the expression of FOXM1, a transcription factor, was upregulated in radioresistant cells compared to parental cells. Targeting FOXM1 showed potential as a therapeutic strategy to overcome radioresistance in OSCC.
LABORATORY INVESTIGATION
(2023)
Article
Developmental Biology
Chao Chen, Xiaomin Kang, Congcong Li, Feng Guo, Qiaohong Wang, Aimin Zhao
Summary: The study investigated the expression of STATs in different stages of pregnancy and their role in trophoblast differentiation. Co-culture model showed DSCs promoted trophoblast differentiation into EVT by regulating the STAT expression. Silencing of STATs in HTR-8/SVneo cells affected the expression of MMPs and integrins.
Article
Biochemistry & Molecular Biology
Jin Zhang, Jiankai Wei, Haiyan Yu, Bo Dong
Summary: The study identified 553 transcription factors classified into 60 families from Styela clava based on whole genome data, particularly focusing on their expression during early embryonic development. Analysis of transcription factors among different tunicate species revealed significant differences in the zinc finger superfamily, suggesting its potential role in species differentiation and environmental adaptation. The discovery of eight Hox genes located on one chromosome and 23 forkhead box genes in Styela clava provided insights into their potential functions in neurodevelopment and sensory organ development.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Cell Biology
Jinfeng Zhu, Jiefeng Zhao, Chen Luo, Zhengming Zhu, Xingyu Peng, Xiaojian Zhu, Kang Lin, Fanqin Bu, Wenjun Zhang, Qing Li, Kai Wang, Zhigang Hu, Xin Yu, Leifeng Chen, Rongfa Yuan
Summary: The FAT10-FOXM1 axis plays a crucial role in promoting proliferation and gemcitabine resistance in pancreatic cancer. FAT10 stabilizes the expression of FOXM1 to influence the growth and drug resistance of pancreatic cancer cells. These findings provide novel insights into chemotherapy resistance in pancreatic cancer.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Xiaoman Bi, Dehua Zheng, Jiale Cai, Dahua Xu, Liyang Chen, Zhizhou Xu, Meng Cao, Peihu Li, Yutong Shen, Hong Wang, Wuping Zheng, Deng Wu, Shaojiang Zheng, Kongning Li
Summary: Through the study of multi-omics data from over 11,000 patients with 33 different types of human cancers, we found that FOX gene mutations were present in 17.4% of tumor patients. We also discovered high expression heterogeneity of FOX genes across cancer types, partially attributed to genomic or epigenomic alterations. We provided 103 FOX gene-drug target-drug predictions and found potential survival predictive value in FOX gene expression.
Article
Cell Biology
Yingyue Tang, Lena Thiess, Sofia M. E. Weiler, Marcell Toth, Fabian Rose, Sabine Merker, Thomas Ruppert, Peter Schirmacher, Kai Breuhahn
Summary: Background Adherens junctions (AJs) facilitate cell-cell contact and contribute to cellular communication as well as signaling under physiological and pathological conditions. Aberrant expression of AJ proteins is frequently observed in human cancers; however, how these factors contribute to tumorigenesis is poorly understood. In this study we aim to decipher how the AJ constituent a-catenin contributes to liver cancer formation.
CELL COMMUNICATION AND SIGNALING
(2023)